{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Quintanilha JCF"],"funding":["NHGRI NIH HHS","NCI NIH HHS"],"pagination":["82-88"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8799524"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["No biomarkers are available to predict patients at risk of developing hypertension induced by VEGF-pathway inhibitors. This study aimed to identify predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach. The discovery set included 140 sorafenib-treated patients (TARGET study) genotyped for 973 SNPs in 56 genes. The most statistically significant SNPs associated with grade ≥2 hypertension were tested for association with grade ≥2 hypertension in the replication set of a GWAS of 1039 bevacizumab-treated patients from four clinical trials (CALGB/Alliance). In the discovery set, rs444904 (G > A) in PIK3R5 was associated with an increased risk of sorafenib-induced hypertension (p = 0.006, OR = 3.88 95% CI 1.54-9.81). In the replication set, rs427554 "],"journal":["The pharmacogenomics journal"],"pubmed_title":["PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors."],"pmcid":["PMC8799524"],"funding_grant_id":["U10 CA180882","R01 HG009974","P50 CA058223","U24 CA196171","R21 CA139280","U10 CA180821","UG1 CA233373","K07 CA140390"],"pubmed_authors":["Quintanilha JCF","Denning S","Lin D","Skol AD","Innocenti F","Etheridge AS","Crona DJ","Pena CE","Wang J","Racioppi A"],"additional_accession":[]},"is_claimable":false,"name":"PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.","description":"No biomarkers are available to predict patients at risk of developing hypertension induced by VEGF-pathway inhibitors. This study aimed to identify predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach. The discovery set included 140 sorafenib-treated patients (TARGET study) genotyped for 973 SNPs in 56 genes. The most statistically significant SNPs associated with grade ≥2 hypertension were tested for association with grade ≥2 hypertension in the replication set of a GWAS of 1039 bevacizumab-treated patients from four clinical trials (CALGB/Alliance). In the discovery set, rs444904 (G > A) in PIK3R5 was associated with an increased risk of sorafenib-induced hypertension (p = 0.006, OR = 3.88 95% CI 1.54-9.81). In the replication set, rs427554 ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-08T01:49:44.34Z","creation":"2025-04-19T22:48:34.075Z"},"accession":"S-EPMC8799524","cross_references":{"pubmed":["34775477"],"doi":["10.1038/s41397-021-00261-5"]}}